Orexo´s Nomination Committee for the Annual General Meeting 2024
Kurs & Likviditet
Kalender
| 2025-02-06 | Bokslutskommuniké 2024 |
| 2024-11-14 | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | Kvartalsrapport 2024-Q1 |
| 2024-04-29 | Ordinarie utdelning ORX 0.00 SEK |
| 2024-04-26 | Årsstämma 2024 |
| 2024-02-08 | Bokslutskommuniké 2023 |
| 2023-11-02 | Kvartalsrapport 2023-Q3 |
| 2023-10-26 | Extra Bolagsstämma 2023 |
| 2023-07-18 | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | Kvartalsrapport 2023-Q1 |
| 2023-04-19 | Ordinarie utdelning ORX 0.00 SEK |
| 2023-04-18 | Årsstämma 2023 |
| 2023-01-26 | Bokslutskommuniké 2022 |
| 2022-11-03 | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | Kvartalsrapport 2022-Q1 |
| 2022-04-22 | Ordinarie utdelning ORX 0.00 SEK |
| 2022-04-21 | Årsstämma 2022 |
| 2022-01-27 | Bokslutskommuniké 2021 |
| 2021-11-03 | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | Kvartalsrapport 2021-Q1 |
| 2021-04-14 | Ordinarie utdelning ORX 0.00 SEK |
| 2021-04-13 | Årsstämma 2021 |
| 2021-01-28 | Bokslutskommuniké 2020 |
| 2020-11-04 | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | Extra Bolagsstämma 2020 |
| 2020-04-28 | Kvartalsrapport 2020-Q1 |
| 2020-04-17 | Ordinarie utdelning ORX 0.00 SEK |
| 2020-04-16 | Årsstämma 2020 |
| 2020-01-30 | Bokslutskommuniké 2019 |
| 2019-10-24 | Kvartalsrapport 2019-Q3 |
| 2019-07-11 | Kvartalsrapport 2019-Q2 |
| 2019-05-02 | Kvartalsrapport 2019-Q1 |
| 2019-04-14 | Ordinarie utdelning ORX 0.00 SEK |
| 2019-04-11 | Årsstämma 2019 |
| 2019-01-30 | Bokslutskommuniké 2018 |
| 2018-10-25 | Kvartalsrapport 2018-Q3 |
| 2018-07-11 | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | Kvartalsrapport 2018-Q1 |
| 2018-04-13 | Ordinarie utdelning ORX 0.00 SEK |
| 2018-04-12 | Årsstämma 2018 |
| 2018-01-25 | Bokslutskommuniké 2017 |
| 2017-10-19 | Kvartalsrapport 2017-Q3 |
| 2017-07-11 | Kvartalsrapport 2017-Q2 |
| 2017-04-20 | Kvartalsrapport 2017-Q1 |
| 2017-04-07 | Ordinarie utdelning ORX 0.00 SEK |
| 2017-04-06 | Årsstämma 2017 |
| 2017-01-26 | Bokslutskommuniké 2016 |
| 2016-10-20 | Kvartalsrapport 2016-Q3 |
| 2016-07-12 | Kvartalsrapport 2016-Q2 |
| 2016-04-21 | Kvartalsrapport 2016-Q1 |
| 2016-04-18 | Ordinarie utdelning ORX 0.00 SEK |
| 2016-04-15 | Årsstämma 2016 |
| 2016-01-28 | Bokslutskommuniké 2015 |
| 2015-10-22 | Kvartalsrapport 2015-Q3 |
| 2015-07-10 | Kvartalsrapport 2015-Q2 |
| 2015-04-23 | Kvartalsrapport 2015-Q1 |
| 2015-04-16 | Ordinarie utdelning ORX 0.00 SEK |
| 2015-04-15 | Årsstämma 2015 |
| 2015-01-29 | Bokslutskommuniké 2014 |
| 2014-10-22 | Analytiker möte 2014 |
| 2014-10-22 | Kvartalsrapport 2014-Q3 |
| 2014-07-11 | Kvartalsrapport 2014-Q2 |
| 2014-04-25 | Kvartalsrapport 2014-Q1 |
| 2014-04-16 | Ordinarie utdelning ORX 0.00 SEK |
| 2014-04-15 | Årsstämma 2014 |
| 2014-01-30 | Bokslutskommuniké 2013 |
| 2013-10-23 | Kvartalsrapport 2013-Q3 |
| 2013-08-06 | Extra Bolagsstämma 2013 |
| 2013-07-12 | Kvartalsrapport 2013-Q2 |
| 2013-04-26 | Kvartalsrapport 2013-Q1 |
| 2013-04-12 | Ordinarie utdelning ORX 0.00 SEK |
| 2013-04-11 | Årsstämma 2013 |
| 2013-03-13 | 15-7 2013 |
| 2013-01-31 | Bokslutskommuniké 2012 |
| 2012-10-25 | Kvartalsrapport 2012-Q3 |
| 2012-09-21 | 15-7 2012 |
| 2012-07-13 | Extra Bolagsstämma 2012 |
| 2012-07-12 | Kvartalsrapport 2012-Q2 |
| 2012-05-03 | Kapitalmarknadsdag 2012 |
| 2012-04-27 | Kvartalsrapport 2012-Q1 |
| 2012-04-12 | Ordinarie utdelning ORX 0.00 SEK |
| 2012-04-11 | Årsstämma 2012 |
| 2012-01-31 | Bokslutskommuniké 2011 |
| 2011-11-09 | Kvartalsrapport 2011-Q3 |
| 2011-08-10 | Kvartalsrapport 2011-Q2 |
| 2011-05-04 | Kvartalsrapport 2011-Q1 |
| 2011-04-08 | Ordinarie utdelning ORX 0.00 SEK |
| 2011-04-07 | Årsstämma 2011 |
| 2011-02-16 | Bokslutskommuniké 2010 |
| 2011-02-16 | Extra Bolagsstämma 2011 |
| 2010-11-10 | Kvartalsrapport 2010-Q3 |
| 2010-08-20 | Kvartalsrapport 2010-Q2 |
| 2010-05-05 | Kvartalsrapport 2010-Q1 |
| 2010-04-22 | Ordinarie utdelning ORX 0.00 SEK |
| 2010-04-21 | Årsstämma 2010 |
| 2010-02-17 | Bokslutskommuniké 2009 |
| 2009-11-10 | Kvartalsrapport 2009-Q3 |
| 2009-08-21 | Kvartalsrapport 2009-Q2 |
| 2009-05-06 | Kvartalsrapport 2009-Q1 |
| 2009-04-24 | Ordinarie utdelning ORX 0.00 SEK |
| 2009-04-23 | Årsstämma 1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden – October 26, 2023 – Prior to the Annual General Meeting (AGM) in 2024, that will take place on April 26, a Nomination Committee has been appointed. The shareholders having appointed members of the Nomination Committee represent approximately 35 percent of the number of votes in the company, based on the latest known shareholder information. The Nomination Committee consists of:
• Henrik Kjaer Hansen, (chairman, appointed by Novo Holdings A/S)
• Claus Berner Møller, (appointed by ATP)[1]
• Robert Florczykowski, (appointed by Third Dot)[2]
• James Noble, (chairman of the board of Orexo)
The Nomination Committee will prepare proposals to the AGM regarding Chairman of the meeting, Chairman of the Board, Board members, Board member fees, any remuneration for committee work, and fees to the auditor, as well as principles for the composition of the Nomination Committee.
The Nomination Committee’s proposals will be presented in the Notice of the AGM and on Orexo’s website, www.orexo.com. Shareholders who want to submit proposals to the Nomination Committee can do this by sending an e-mail to ir@orexo.com (subject “Nomination Committee”) at latest February 24, 2024.
Orexo AB (publ.)
|
Lena Wange, IR & Communications Director |
|
|
Tel: +46 (0)18 780 88 00 |
|
|
E-mail: ir@orexo.com |
|
About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to SEK 624 million, and the number of employees to 126. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
For more information about Orexo please visit www.orexo.com. You can also follow X, (former Twitter), LinkedIn, and YouTube.
[1] The Danish Labour Market Supplementary Pension
[2] Third Dot´s shareholding in Orexo is registered in a foreign nominee's name, but is confirmed by Euroclear via voting right registration ahead of the extraordinary general meeting on October 26, 2023, and amounted to 705 421 shares
The information was submitted for publication at 5 pm CET on October 26, 2023.